- Home
- HXHX vs RNAZ Comparison
HXHX vs RNAZ Comparison
Compare HXHX & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HXHX | RNAZ |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | China | United States |
| Employees | 85 | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 5.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HXHX | RNAZ |
|---|---|---|
| Price | $0.51 | $8.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 21.2K |
| Earning Date | 05-20-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $3.82 |
| 52 Week High | $1.84 | $20.99 |
Technical Indicators
Market Signals| Indicator | HXHX | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 67.93 |
| Support Level | $0.51 | $8.38 |
| Resistance Level | $0.56 | $9.37 |
| Average True Range (ATR) | 0.06 | 0.89 |
| MACD | 0.01 | 0.47 |
| Stochastic Oscillator | 73.04 | 91.51 |
Price Performance
Historical ComparisonAbout HXHX Haoxin Holdings Limited Class A Ordinary Shares
Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.